Feb 23, 2024 Study Guide For Medication Treatment Schizophrenia Spectrum And Other Psychosis Disorders Nurs 6630
A Sample Answer For the Assignment: Study Guide For Medication Treatment Schizophrenia Spectrum And Other Psychosis Disorders Nurs 6630
Mental illness is known to have various negative impacts on patients’ lives. Among them are schizophrenia spectrum and other psychosis disorders (Jester et al.,2023). These illnesses usually result in undesirable symptoms like delusions, hallucinations, disorganized thinking or speech, and disorganized or abnormal motor behaviors. As such, the PMHNPs should possess sufficient knowledge concerning these conditions and their symptoms for accurate diagnosis, treatment, and management. Study guides can play a critical role in enhancing a person’s ability to learn about these conditions and their management using antipsychotic agents. Therefore, the purpose of this assignment is to create a study guide that presents the medication treatment for schizophrenia spectrum and other psychosis disorders.
Drug Description
The chosen medication for this study guide is Quetiapine. This mediation has widely been used in treating schizophrenia (de Miranda et al.,2020). The brand name is Seroquel. The FDA approved this medication to be used in treating schizophrenia, major depressive disorder, and bipolar disorder.
Non-FDA uses
Apart from the FDA indications, Seroquel has also been used for non-FDA-approved functions. The non-FDA uses include the following.
Treatment of insomnia where low doses are usually given
Treatment of alcohol dependence as heavy drinkers has been observed to reduce their drinking tendencies when using the medication (de Miranda et al.,2020)
It is also used in the treatment of general anxiety disorder, where lower doses are used.
Drug classification
Seroquel is an antipsychotic under second-generation antipsychotics.
Struggling to Meet Your Deadline?
Get your assignment on Study Guide For Medication Treatment Schizophrenia Spectrum And Other Psychosis Disorders Nurs 6630 done on time by medical experts. Don’t wait – ORDER NOW!
Meet my deadline
Mechanism of actionPharmacokineticsPharmacodynamicsIt is known to act on the dopaminergic D1 and D2 receptors. It is also an antagonist for serotonin receptors and D2 receptors.Absorption: An immediate and extended release of 1.5 hours and 6 hours, respectively (Peak plasma time) The medication blocks the dopamine receptors to help lower incidences of delusions and hallucinations caused by schizophrenia. Acts on dopaminergic D1 and D2 receptors.Metabolism: The medication metabolism takes place in the liver by CYP3A4 (Badhan & Macfarlane, 2020) Elimination: 20% of elimination is through feces, while 73% is through excretion.
Recommended dosing:
150-750 mg/day (Immediate release); 400-800 mg/day (extended-release).
Children below twelve years: No safety has been established.
Children above twelve years: 400-800 mg/day
Not recommended for breastfeeding and pregnant women
Geriatrics: 50-200 mg/day (Immediate); 50 mg/day (Extended) (de Miranda et al.,2020)
Route of Administration: The medication is taken through the mouth
Dosing alterations consideration: individuals susceptible to hypotensive reactions and the elderly.
Half-life: This is the time which is taken by a medication’s concentration to reduced by half of the original concentration in the body. It is important to understand the half-life of medication since it dictates the steady-state concentration and excretion. The half-life for Seroquel is six hours for immediate release and seven hours for extended-release (de Miranda et al.,2020).
Side Effects and Possible Adverse Reactions
The medication is connected to various side effects and possible adverse reactions, which might be a concern to patients. It is important that a patient is educated regarding the same. They are illustrated below.
Contraindications For Use Including Significant Drug-To-Drug Interactions
The medication is contraindicated for patients with hypersensitivity. The medication has been shown to pause and increase mortality risk in elderly individuals displaying dementia-connected psychosis. It may interact with medication that, leads to prolonged QT intervals. The medication specifically interacts with Leuprolide, Lefamulin, Goserelin, and Amisupride (Oruch et al.,2020).
Overdose Considerations
The medication can lead to death in cases of overdose. Indeed, toxicity may happen with levels higher than 1500 ng/mL.
Supportive care has widely been used in treating Seroquel overdose.
Measures for acute toxicity include ventilation, sufficient oxygenation, and maintaining the airway (Oruch et al.,2020).
Gastric lavage and administration of activated charcoal with a laxative can also help in stopping the absorption of the drug if administered.
Diagnostics and labs monitoring
Comorbidities considerations
Practitioners should monitor the blood glucose levels of patients with diabetes mellitus to limit the chances of hyperosmolar coma (Osborne et al.,2020).
Practitioners should be careful with individuals with hypomagnesemia, cardiac arrhythmia, and hypokalemia and should get a metabolic panel before they can start administering the medication.
Legal and ethical considerations
Health practitioners have to uphold the patient’s health information confidentiality as a way of preventing legal issues (Limandri, 2019)
It is also important to uphold beneficence by ensuring that administered medication leads to optimum benefits when treating the approved indications for the medication.
The practitioners should also consider the side effects of the medication and ensure that the expected benefits outweigh the potential risks hence upholding nonmaleficence.
Consent is also required. Therefore, the health practitioners should obtain consent from the patients and ensure that the patient is well informed regarding the potential side effects and adverse effects of Seroquel.
Pertinent Patient Education Considerations
It is important to explore pertinent patient education considerations when administering Seroquel. As such, the practitioner has to educate the patient regarding various aspects, such as side effects, potential benefits, and indications. The patients should be educated on the need to adhere to the medication regimen and ensure that they see they visit the facility in case of any adverse effects or reactions (de Miranda et al.,2020).
. In addition, the patient also needs to be informed of the instances when the medication can be discontinued.
Conclusion
This study guide has explored the use of Seroquel, which is an FDA-approved medication for treating schizophrenia, major depressive disorder, and bipolar disorder. The medication also has various non-FDA-approved uses, such as the treatment of insomnia and generalized anxiety disorder. The guideline has also explored various aspects such as indications for use, contraindication, potential side effects and adverse reactions, diagnostics and lab monitoring, and various ethical principles to consider.
References
Badhan, R. K., & Macfarlane, H. (2020). Quetiapine dose optimisation during gestation: A pharmacokinetic modelling study. Journal of Pharmacy and Pharmacology, 72(5), 670–681. https://doi.org/10.1111/jphp.13236
de Miranda, A. S., Ferreira, R. N., Teixeira, A. L., & de Miranda, A. S. (2020). Mood Stabilizers: Quetiapine. NeuroPsychopharmacotherapy, 1-23.
Jester, D. J., Thomas, M. L., Sturm, E. T., Harvey, P. D., Keshavan, M., Davis, B. J., … & Jeste, D. V. (2023). Review of major social determinants of health in schizophrenia-spectrum psychotic disorders: I. Clinical outcomes. Schizophrenia Bulletin, 49(4), 837–850. https://doi.org/10.1093/schbul/sbad023
Limandri, B. J. (2019). Ethical Reasoning in Prescribing and Monitoring Psychotropic Medications. Journal of Psychosocial Nursing and Mental Health Services, 57(1), 7-10. https://doi.org/10.3928/02793695-20181212-03
Oruch, R., Pryme, I., Fasmer, O., & Lund, A. (2020). Quetiapine: An objective evaluation of pharmacology, clinical uses and intoxication. EC Pharmacol Toxicol, 8, 1-26. https://elibrary.ru/item.asp?id=42474663
Osborne, V., Davies, M., Evans, A., & Shakir, S. (2020). Observational assessment of safety in Seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England. Therapeutic advances in psychopharmacology, 10, 2045125320954616. https://doi.org/10.1177/2045125320954616
Description Of the Psychopharmacological Medication Agent
Cariprazine is a psychopharmacological drug sold under the brand name Vraylar. It is an adult atypical antipsychotic drug of the second generation prescribed to treat schizophrenia and bipolar disorder. Cariprazine acts by altering dopamine and serotonin quantities in the brain, which alleviates symptoms including mania, hallucinations, and disordered thinking. The drug is offered as tablets and is typically ingested once daily.
Cariprazine has been given FDA approval for the management of schizophrenia and adult-onset bipolar disorder. Cariprazine is recommended for schizophrenia as a monotherapy or as an additional medication to lessen relapse frequency (Pinto et al., 2019). In individuals with bipolar I disorder who have responded to initial therapy, cariprazine is recommended for the acute management of manic or mixed episodes and for the maintenance of a calm mood.
Research for Non-FDA Uses
One area of research interest has been the use of cariprazine for the treatment of major depressive disorder (MDD). Several clinical trials have been conducted to evaluate the efficacy and safety of cariprazine as an adjunctive treatment for MDD, with some studies showing promising results. A study found that cariprazine as an adjunctive treatment to an antidepressant was effective in reducing depressive symptoms in patients with MDD who had not responded to prior antidepressant treatment (Pinto et al., 2019).
Another potential non-FDA use of cariprazine is for the treatment of substance use disorders. Preclinical studies have suggested that cariprazine may be effective in reducing drug-seeking behavior and reinstatement of drug use in animal models of addiction. Additionally, a pilot study published in the Journal of Dual Diagnosis in 2018 found that cariprazine may be useful for the treatment of cocaine use disorder in humans.
Drug Classification
Cariprazine is classified as a second-generation atypical antipsychotic medication. This class of drugs is used to treat various psychiatric disorders, including schizophrenia and bipolar disorder, by modulating the levels of dopamine and other neurotransmitters in the brain (Pinto et al., 2019). Second-generation atypical antipsychotics are considered to be a newer class of antipsychotic drugs compared to first-generation antipsychotics, and they have been developed to offer better efficacy and fewer side effects.
Cariprazine is structurally similar to aripiprazole, another atypical antipsychotic medication. Both medications are partial agonists at the dopamine D2 receptor and the serotonin 5-HT1A receptor, which means that they can stimulate or inhibit these receptors depending on the level of activity of the neurotransmitter. This unique pharmacological profile is thought to contribute to the efficacy and tolerability of cariprazine in the treatment of psychiatric disorders.
Mechanism of Action
Cariprazine’s mechanism of action is complex and involves modulation of multiple neurotransmitter systems in the brain, including dopamine and serotonin. Specifically, cariprazine acts as a partial agonist at dopamine D2 and D3 receptors and a partial agonist at serotonin 5-HT1A receptors, while also acting as an antagonist at serotonin 5-HT2A receptors (Laszlovszky et al., 2021).
Study Guide For Medication Treatment Schizophrenia Spectrum And Other Psychosis Disorders Nurs 6630
The partial agonist activity at dopamine D2 and D3 receptors allows cariprazine to modulate the dopaminergic pathways in the brain, which are known to be involved in the pathophysiology of schizophrenia and bipolar disorder. By acting as a partial agonist, cariprazine can both stimulate and inhibit these receptors, depending on the level of dopamine activity in the brain. This unique pharmacological profile is thought to contribute to the medication’s ability to improve symptoms such as delusions, hallucinations, and disorganized thinking.
In addition to its effects on dopamine, cariprazine also has partial agonist activity at serotonin 5-HT1A receptors, which are involved in the regulation of mood, anxiety, and cognition. By modulating the activity of these receptors, cariprazine may help to improve symptoms of depression and anxiety that are commonly associated with schizophrenia and bipolar disorder.
Pharmacokinetics and Pharmacodynamics
Cariprazine is an orally administered medication that is rapidly absorbed by the body, with peak plasma concentrations occurring within 3-4 hours of ingestion. The bioavailability of cariprazine is estimated to be approximately 52%, which means that about half of the medication reaches systemic circulation following oral administration (Laszlovszky et al., 2021).
Once absorbed, cariprazine is extensively metabolized in the liver by enzymes such as cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2D6 (CYP2D6). The metabolites of cariprazine are primarily eliminated through urine and feces, with approximately 26% of the dose being eliminated in urine and 51% in feces.
Cariprazine acts as an antagonist at serotonin 5-HT2A receptors, which are involved in the regulation of sensory perception, cognition, and mood. By blocking the activity of these receptors, cariprazine may help to reduce the risk of side effects such as hallucinations and agitation that are associated with other antipsychotic medications.
Appropriate Dosing, Administration Route, and any Considerations for Dosing Alterations
The recommended starting dose for cariprazine in the treatment of schizophrenia is 1.5 mg/day, taken orally with or without food. The dose may be increased gradually over several days to a target dose of 4.5 mg/day, based on the patient’s response and tolerability. The maximum recommended dose is 6 mg/day.
For the treatment of bipolar disorder, the recommended starting dose is 1.5 mg/day, taken orally with or without food (Fagiolini et al., 2020). The dose may be increased gradually over several days to a target dose of 3 mg/day, based on the patient’s response and tolerability. The maximum recommended dose is 6 mg/day.
Cariprazine is available in tablet form and should be taken orally once daily, before or after meals. The tablets should be swallowed whole and should not be crushed or chewed (Fagiolini et al., 2020). Cariprazine may interact with other medications that affect the metabolism of the medication, such as CYP3A4 and CYP2D6 inhibitors or inducers. Patients taking these medications may require a dose adjustment of cariprazine to ensure optimal efficacy and tolerability.
Considerations Of Use and Dosing in Specific Specialty Populations
Children and adolescents
Not approved for use in children and adolescents under the age of 18 years old.
Elderly
Elderly patients may be more sensitive to the effects of cariprazine due to changes in metabolism and clearance of the medication (Fagiolini et al., 2020). Therefore, the dose may need to be adjusted in elderly patients to avoid adverse effects such as sedation, orthostatic hypotension, or extrapyramidal symptoms.
Pregnancy and breastfeeding
Cariprazine should only be used during pregnancy or breastfeeding if the potential benefits to the mother outweigh the potential risks to the fetus or infant.
Suicidal behaviors
May increase the risk of suicidal thoughts or behaviors, especially in children and young adults. Patients should be closely monitored for signs of suicidal ideation, especially during the first few months of treatment or after a change in dose.
Half-life
Half-life is the amount of time it takes for half of the initial dose of a drug to be eliminated from the body. The half-life of a medication is important because it determines the frequency and timing of dosing and can affect the drug’s efficacy and potential for adverse effects (Fagiolini et al., 2020). The half-life of cariprazine is approximately 2-4 days, meaning it takes 2-4 days for half of the initial dose of cariprazine to be eliminated from the body.
This relatively long half-life suggests that cariprazine may be suitable for once-daily dosing, but it may take longer to reach a steady state and may require a longer time to clear from the body if dosing is discontinued. The half-life of cariprazine should be taken into account when determining appropriate dosing regimens and monitoring for potential adverse effects.
Side effects
Common side effects of cariprazine include:
Restlessness
Extrapyramidal symptoms (such as tremors or muscle stiffness)
Sedation
Nausea
Vomiting
Constipation
Headache
Weight gain
Contraindications for use including significant drug to drug interactions
Contraindications for the use of cariprazine include:
Hypersensitivity to cariprazine or any component of the formulation
Unstable heart disease
QTc prolongation
Severe hepatic impairment
Severe renal impairment
Known history of prolonged QT syndrome
Significant drug-to-drug interactions include:
Strong CYP3A4 inhibitors can increase the concentration of cariprazine in the body, potentially leading to increased side effects (Edinoff et al., 2020).
Strong CYP3A4 inducers (such as rifampin and phenytoin) can decrease the concentration of cariprazine in the body, potentially reducing its efficacy.
Overdose Considerations
An overdose of cariprazine can be dangerous and potentially life-threatening. Symptoms of an overdose may include severe sedation, seizures, confusion, cardiac arrhythmias, and respiratory depression (Edinoff et al., 2020). In the event of an overdose, immediate medical attention should be sought.
Diagnostics and labs monitoring
Complete blood count
Liver function tests
Electrolyte levels
Comorbidities Considerations
Cardiovascular disease: Cariprazine can cause changes in blood pressure and heart rate, so caution is advised in patients with cardiovascular disease. Blood pressure and heart rate should be monitored regularly during treatment.
Diabetes: Cariprazine can cause changes in blood glucose levels, so caution is advised in patients with diabetes. Blood glucose levels should be monitored regularly during treatment.
Seizure disorder: Cariprazine can lower the seizure threshold, so caution is advised in patients with a history of seizures or epilepsy (Edinoff et al., 2020).
Renal or hepatic impairment: Cariprazine is metabolized in the liver and excreted in the kidneys, so caution is advised in patients with renal or hepatic impairment. Dose adjustments may be necessary.
Substance use disorder: Cariprazine may have potential for abuse or dependence, so caution is advised in patients with a history of substance use disorder.
Pregnancy or breastfeeding: The safety of cariprazine during pregnancy and breastfeeding is not well-established, and the potential risks and benefits should be carefully considered before prescribing to women who are pregnant or breastfeeding.
Legal and Ethical Considerations
One of the most critical legal considerations is obtaining informed consent from patients. Healthcare providers must explain the potential benefits and risks of cariprazine, as well as any alternative treatments that may be available. Informed consent is critical to ensuring that patients understand the implications of taking medication, and that they are fully informed about their treatment options. Another legal consideration is the off-label use of cariprazine.
While cariprazine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, healthcare providers may also prescribe it for off-label uses (Rancans et al., 2021). Off-label use is legal, but it must be based on clinical judgment and the best available evidence. Providers should also be aware of any potential legal risks associated with off-label use.
Prescribing practices are also essential legal and ethical considerations. Healthcare providers must prescribe cariprazine at the appropriate dosage and monitor patients for side effects or adverse reactions. Providers should also follow established medical guidelines and best practices when prescribing cariprazine or any other medication.
Healthcare providers must protect patient privacy by following all relevant privacy laws and regulations, such as HIPAA. This includes keeping patient medical records confidential and only sharing information with other healthcare providers on a need-to-know basis. Finally, healthcare providers may be held liable for any harm that their patients experience as a result of medication errors or other negligent actions.
Pertinent Patient Education Considerations
Dosing and administration
Patients should be educated on how to take cariprazine, including the appropriate dosage and administration route. Patients should also be advised to take the medication as directed by their healthcare provider and not to adjust their dose or stop taking the medication without consulting their provider.
Side effects and adverse reactions
Patients should be informed about the potential side effects and adverse reactions of cariprazine. They should be advised to contact their healthcare provider immediately if they experience any side effects, such as dizziness, nausea, or constipation.
Drug interactions
Patients should be informed of potential drug interactions with cariprazine, including over-the-counter medications, herbal supplements, and other prescription drugs. Patients should be advised to consult their healthcare provider before taking any new medications (Rancans et al., 2021).
Importance of compliance
Patients should be educated on the importance of compliance with their cariprazine treatment regimen. Skipping doses or discontinuing treatment without consulting their healthcare provider can lead to a worsening of their condition.
Pregnancy and breastfeeding
Patients should be informed abou
Order a similar assignment, and have writers from our team of experts write it for you, guaranteeing you an A
